JP2024540083A - 抗NRP2a抗体を含む組成物及び方法 - Google Patents

抗NRP2a抗体を含む組成物及び方法 Download PDF

Info

Publication number
JP2024540083A
JP2024540083A JP2024525338A JP2024525338A JP2024540083A JP 2024540083 A JP2024540083 A JP 2024540083A JP 2024525338 A JP2024525338 A JP 2024525338A JP 2024525338 A JP2024525338 A JP 2024525338A JP 2024540083 A JP2024540083 A JP 2024540083A
Authority
JP
Japan
Prior art keywords
cancer
antigen
antibody
optionally
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024525338A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540083A5 (cg-RX-API-DMAC7.html
Inventor
ルーク ジー. バーマン,
イーティン チョン,
ケイトリン ラウチ,
レスリー エー. ナングル,
Original Assignee
エータイアー ファーマ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エータイアー ファーマ, インコーポレイテッド filed Critical エータイアー ファーマ, インコーポレイテッド
Publication of JP2024540083A publication Critical patent/JP2024540083A/ja
Publication of JP2024540083A5 publication Critical patent/JP2024540083A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2024525338A 2021-10-27 2022-10-27 抗NRP2a抗体を含む組成物及び方法 Pending JP2024540083A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163272374P 2021-10-27 2021-10-27
US63/272,374 2021-10-27
PCT/US2022/078780 WO2023076998A1 (en) 2021-10-27 2022-10-27 COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2a ANTIBODIES

Publications (2)

Publication Number Publication Date
JP2024540083A true JP2024540083A (ja) 2024-10-31
JP2024540083A5 JP2024540083A5 (cg-RX-API-DMAC7.html) 2025-08-28

Family

ID=86158721

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024525338A Pending JP2024540083A (ja) 2021-10-27 2022-10-27 抗NRP2a抗体を含む組成物及び方法

Country Status (7)

Country Link
US (1) US20240417476A1 (cg-RX-API-DMAC7.html)
EP (1) EP4423142A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024540083A (cg-RX-API-DMAC7.html)
CN (1) CN118355033A (cg-RX-API-DMAC7.html)
AU (1) AU2022375785A1 (cg-RX-API-DMAC7.html)
CA (1) CA3234409A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023076998A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195770A1 (en) 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
AU2020358854B2 (en) 2019-10-03 2026-08-13 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021067761A1 (en) * 2019-10-03 2021-04-08 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7420040B2 (en) * 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
AR068723A1 (es) * 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
NZ594514A (en) * 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
JP5812418B2 (ja) * 2009-04-17 2015-11-11 イムナス・ファーマ株式会社 Aβオリゴマーに特異的に結合する抗体およびその利用
EP2700652B1 (en) * 2011-04-18 2018-12-19 The University of Tokyo Diagnosis and treatment of cancer using anti-itm2a antibody
DK2935331T3 (en) * 2012-12-24 2018-06-06 Abbvie Inc PROLACTIN RECEPTOR BINDING PROTEINS AND APPLICATIONS THEREOF
EP3116906A1 (en) * 2014-03-12 2017-01-18 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg1-3
US11104724B2 (en) * 2016-05-23 2021-08-31 New York University Compositions and methods for antibodies targeting staphylococcal leukotoxins
US12365916B2 (en) * 2017-10-30 2025-07-22 Miltenyi Biotec B.V. & Co. KG Adapter-based retroviral vector system for the selective transduction of target cells
WO2019195770A1 (en) * 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
MX2021011489A (es) * 2019-04-01 2021-10-22 Jiangsu Hengrui Medicine Co Anticuerpo anti-claudina 18.2 y utilizacion del mismo.
ES3049416T3 (en) * 2019-09-23 2025-12-16 Centro Nac De Investigaciones Cardiovasculares Carlos Iii F S P Antibodies for the diagnosis and/or treatment of atherosclerosis
WO2021202590A1 (en) * 2020-03-31 2021-10-07 Alector Llc Anti-mertk antibodies and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021067761A1 (en) * 2019-10-03 2021-04-08 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies

Also Published As

Publication number Publication date
CN118355033A (zh) 2024-07-16
AU2022375785A1 (en) 2024-04-11
WO2023076998A1 (en) 2023-05-04
EP4423142A1 (en) 2024-09-04
CA3234409A1 (en) 2023-05-04
EP4423142A4 (en) 2025-10-22
US20240417476A1 (en) 2024-12-19

Similar Documents

Publication Publication Date Title
US12065495B2 (en) Compositions and methods comprising anti-NRP2 antibodies
JP7701913B2 (ja) 抗nrp2抗体を含む組成物および方法
US20180282402A1 (en) Anti-hrs antibodies and combinaton therapies for treating cancers
AU2020405036A1 (en) ILT3-binding agents and methods of use thereof
US20240417476A1 (en) COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2a ANTIBODIES
CN120858108A (zh) 抗il-18bp抗体
WO2021257808A2 (en) Antibodies to fibroblast activation protein and b7h3
US20250188170A1 (en) COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2b ANTIBODIES

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250820

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260615